Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIXUBIS in Hemophilia B in India
NCT03565237Phase 4Completed
- Sponsor
- Takeda
- Start
- Dec 2018
- Primary completion
- Aug 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of trenonacog alfa in hemophilia B (HB), sponsored by Takeda. Started Dec 2018; status: completed.
02
Drugs
trenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03565237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565237.